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Patients undergoing total knee arthroplasty (TKA) report low satisfaction with postoperative pain control.
The purpose of this study is to examine if there is a difference in post-operative pain for TKA patients
without femoral nerve block receiving an intra-operative pericapsular injection of bupivacaine liposome
suspension (EXPAREL; Pacira Pharmaceuticals, Inc., San Diego, California) versus a concentratedmulti drug
cocktail. Seventy TKA patients were randomly assigned to either the bupivacaine liposome or the multi-
drug cocktail. Post-operative pain scores, morphine sulfate equivalence consumption values, adverse
events, and overall pain control satisfaction scores were collected. Patients reported signiﬁcantly higher
pain level for the cocktail group on post-op day 1 (p < .05) and post-op day 2 (p < .01) versus the bupi-
vacaine liposome group. This same trend was found for morphine sulfate equivalence consumption in the
PACU (p < .01) and post-op day 2 (p < .01). Higher satisfaction in pain control (p < .001) and overall
experience (p < .01) was also found in the bupivacaine liposome group. Finally, signiﬁcantly more adverse
events were found in the multi-drug group versus the bupivacaine liposome group (p < .05). The study
ﬁndings demonstrated a non-inferior difference, albeit not a clinically signiﬁcant difference, in
patient-perceived pain scores, morphine sulfate equivalence consumption, adverse events, and overall
satisfaction.
Copyright © 2016 Published by Elsevier Inc. on behalf of American Association of Hip and Knee Surgeons.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Postoperative pain can have a major effect on patient recovery
through decreased patient satisfaction and prolonged rehabilita-
tion. Although pain is a predictable part of the postoperative
experience, inadequate management of pain is common and can
have profound implications. Despite guidelines and recommenda-
tions from pain management societies, postoperative pain con-
tinues to be viewed as a major health care concern [1].closed potential or pertinent
ent, either direct or indirect,
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d/4.0/).Total knee arthroplasty (TKA) is a common surgical procedure
which can cause a considerable amount of pain. Multimodal pain
management reduces postoperative pain in the majority of TKA
patients [2e10] yet too many patients are still dissatisﬁed with
overall pain control [8] and adverse drug reactions to neuroleptic
and opioid medications prescribed. Additionally, the common use
of femoral nerve blocks as a pain control measure has demon-
strated to have several concerning issues such as hindering early
physical therapy, contributing to increased fall rates [11], and new
neurological symptoms associated with a block [12].
Pain management therapy, which includes surgical site inﬁltra-
tion of an anesthetic, is one of the latest methods being used to
decrease postoperative pain [8]. Several agents have been used for
this method; however a new method using liposomal bupivacaine
has recently been introduced. Liposomal bupivacaine suspension is a
non-opioidmedication using Depofoam technologywhich allows for
extended release of pericapsular injected bupivacaine for up to
72 hours postoperatively [13,14]. There is one recent randomizedn of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND
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different surgical procedures, that favorably compared pericapsular
injection with bupivacaine liposome suspension versus bupivacaine
hydrochloride (HCL) [15,16]. The liposome suspension provided a
considerable longer amount of pain relief when compared to the
hydrochloride [15,17]. To date, the clinical use and published evi-
dence supports bupivacaine liposome suspension in patients un-
dergoing bunionectomy or hemorrhoidectomy [16], however with a
paucity of available data, future research is desperately needed.
We suspect hospitalized TKA patients without a pre-operative
femoral nerve block will experience a non-inferior postoperative
pain control and MSO4 (morphine sulfate) equivalence consump-
tion when receiving an injection of bupivacaine liposome suspen-
sion (EXPAREL; Pacira Pharmaceuticals, Inc., San Diego, California)
versus a concentrated multi drug cocktail.
Material and methods
This prospective randomized, double blind controlled trial was
conducted at a large community hospital with approval from theFigure 1. CONSORT 2010 Bupivacaine Study Randomization Flow Diagram. Tinternal Institutional Review Board. Subjects were at least 18 years
of age and received a TKA for degenerative joint disease, due to
failing all other non-operative treatments to control knee pain.
Subjects were excluded from the study if they were found to have a
history of orthopedic and medical co-morbidities that would pre-
vent postoperative pain control (i.e. extra-articular pathology with
referred pain to the knee associated with spinal stenosis, neurop-
athy, and ipsilateral hip disease), severe knee deformity, post-
traumatic, and inﬂammatory arthritis, BMI >40, were unable to
receive multimodal pain remitting agents, had active knee sepsis,
had remote sites of active infection, had diabetes with A1C > 7,
American Society of Anesthesiologists class (ASA) > III, cardiac
disease failing medical clearance, severe liver disease, peripheral
artery disease (PAD) with ankle arm index (AAI) < .75, seizure
disorder, allergic to any pain remitting agent, alcohol abuse, or
smoking abuse (Fig. 1).
This study was registered with ClinicalTrials.gov, record 13055-
13-034. The protocol and all other study related documents are
retained at the research facility responsible for conducting the
study.his diagram displays the progress of all subjects throughout the study.
Figure 2. Subject Randomization Flowchart. This ﬂowchart depicts how subjects were randomized at a 1:1 ratio to either the bupivacaine liposomal suspension injection or the
concentrated cocktail mixture injection. Further detail shows the type of anesthesia each group received.
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the potential risks and beneﬁts of each medication potentially be-
ing administered, written informed consent was obtained per the
research nurse. After enrollment, subjects were randomized at a
1:1 ratio per permuted block randomization table to either the
bupivacaine liposomal suspension injection or the concentrated
cocktail mixture injection by a pharmacist (Fig. 2). Neither the
patient nor the surgeonwere aware of to which group each subject
had been randomized.
On the day of surgery, the randomized drug was prepared in
pharmacy and brought to the operating room. Due to the dissimilar
color of the medications used, the drug was transferred to a sterile
syringe covered in opaque coban to blind the surgeon from sub-
jects' randomization group. Subjects were anesthetized by either
regional spinal anesthesia consisting of .75% ropivicaine or general
anesthesia consisting of a 1% propofol (10 mg/ml) continuous drip
(Table 1). The randomized pericapsular injection was delivered
during the surgery. Thirty percent of the medication was slowly
injected into the post capsular region of the knee using an 18 gauge
needle prior to the cementation of the implants. The remaining 70%
of the medication was then equally inﬁltrated into the surrounding
soft tissue using an 18 gauge needle and a precise delivery tech-
nique to evenly deposit the drug. Once surgery was complete, the
patient was transferred to PACU where postoperative pain assess-
ments began using a numerical rating scale (NRS) ranging from
0 (No pain) to 10 (Worst possible pain) [18]. Both verbal pain scores
and total opioid (morphine equivalence) consumption were
collected for each day. Additionally, postoperative overall pain
control satisfaction scores were collected using a 5 point Likert-
type scale ranging from 1 (Not at all satisﬁed) to 5 (Extremely
satisﬁed) at the 10 day follow-up visit with the surgeon. Adverse
events were also collected and documented for each subject.
Statistical analysis was performed using IBM SPSS Statistics for
Windows version 21 (Armonk, NY: IBM Corp.). Univariate chi-square analysis was incorporated for all categorical variables and
for expected cell counts <5, a Fisher's exact test was employed. For
continuous variables, independent-samples t-test was performed
and for non-normal continuous variables, a ManneWhitney U test
was used for mean comparison.
There was no external source of funding for this study. All
medications administered for study purposes were provided by the
research institution's hospital pharmacy.
Results
A total of 126 patients were screened against inclusion/exclu-
sion criteria for participation in the study, but a total of 70 were
included in the analysis (Fig. 1). This was enough to justify using an
independent-sample t-test given this tests ability to handle smaller
sample sizes in it's a priori assumptions with a reasonable expected
difference between groups. In addition, the non-parametric
ManneWhitney U has even less assumptions, so this was the
default test for non-normal distributions. Majority of the subjects
were white (98.1%) male (52.8%) with a mean age of 66.4 years
(9.1 years) and a mean BMI of 30.9 (4.5). About 55% of patients had
an ASA score of II and 74.3% of patients received spinal anesthesia.
With regards to comorbidities, 8.57% of patients had coronary ar-
tery disease, 20% were diabetic, 57.14% were hypertensive, and just
over 1.43% suffered from atrial ﬁbrillation. A statistical signiﬁcance
difference of p < .05 was considered signiﬁcant. There were no
statistically signiﬁcant differences reported in the above de-
mographics, anesthesia scores, anesthesia type, and comorbidities,
thus indicating homogenous groups. The only adverse event
reported was nausea, which 40% of subjects reported. Of this 40%,
67.9% were in the concentrated multi-drug cocktail group versus
only 32.1% in the bupivacaine liposomal suspension group. This
difference was statistically signiﬁcant (p < .05). These and other
descriptive statistics can be found in Table 2.
Table 1
Periarticular injection.
Bupivacaine liposome injection Concentrated multi drug injection
▪ 266 mg reconstituted to 100 ml with .9% NaCl ▪ Ketorolac 30 mg
▪ Morphine PF 5 mg
▪ Epinephrine 0.6 mg
▪ Ropivicaine 400 mg
▪ Quantity sufﬁcient to 100 ml with .9% NaCl
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post op in the PACU and throughout the patient's hospitalization. In
the PACU patients reported a signiﬁcantly lower score in the
bupivacaine liposomal suspension M ¼ 2.11 (2.68) versus the
concentrated multi-drug cocktail group M ¼ 3.49 (2.87) (p < .05).
Postoperatively, patients also reported lower scores in the
bupivacaine liposomal suspension group versus the concentrated
multi-drug cocktail group on Postoperative day (POD)#0, POD#1,
and POD#2, with signiﬁcant differences on POD#1 and POD#2,
p < 05, p < .01, respectively. Statistical tests could not be performed
for POD#3, due to lack of statistical testing assumptions being
made, speciﬁcally with regards to homogeneity of variance. No
patients were in the hospital 4 days postoperatively, so no data
were reported. More objective measurements were also used in
addition to patient reported pain scores, speciﬁcally using the
morphine sulfate equivalence consumption tables for all patients.
Patients in the bupivacaine liposomal suspension group consumed
less narcotics in the PACU, as well as everyday postoperatively
(POD#0-POD#2) when compared to patients in the concentrated
multi-drug cocktail group with signiﬁcant differences reported in
the PACU (p < .01) and on POD#2 (p < .01). Statistical testing was
also not performed for MS04 equivalency scores on POD#3 or
POD#4 for reasons stated above. Patient reported NRS pain scoresTable 2
Patient demographics.
Total sample
n (%)
N ¼ 70
Concentrated multi-d
n (%)
N ¼ 35
Demographics
Age (yrs), mean (SD)d 66.54 (9.14) 65.57 (7.89)
BMI, mean (SD)d 30.98 (4.45) 31.29 (4.70)
Genderc
Male 37 (52.9) 15 (42.9)
Female 33 (47.1) 20 (57.1)
Raceb
Caucasian 69 (98.60) 34 (97.10)
African American 1 (1.40) 1 (2.90)
Anesthesia
ASA scorec
I 4 (5.70) 2 (5.71)
II 39 (55.7) 20 (57.14)
III 27 (38.6) 13 (37.1)
Anesthesia typec
General 18 (25.71) 12 (34.29)
Spinal 52 (74.29) 23 (65.71)
Comorbidities
CADb 6 (8.57) 2 (5.71)
Diabetesb 7 (20.00) 4 (11.43)
Hypertensionb 40 (57.14) 18 (51.43)
A-Fibb 1 (1.43) 0 (.00)
Adverse event
Nauseac 28 (40.00) 19 (54.29)
CA ¼ Coronary artery disease, A-ﬁb ¼ Atrial ﬁbrillation.
a Statistically signiﬁcant at the p < .05 level.
b Fisher's exact Test.
c Univariate chi-square analysis.
d Independent-samples t-test.and morphine sulfate equivalency comparisons can be found in
Table 4.
Patient satisfaction with in-hospital pain control, as well as 10
days postoperative pain control was assessed using a 5 point
Likert-type scale ranging from 1 (not at all satisﬁed) to 5
(extremely satisﬁed). Patients assigned to the bupivacaine lipo-
somal suspension group reported both higher satisfaction with
pain control overallM¼ 4.57 (SD¼ .70) as well as satisfactionwith
pain control while they were in the hospital M ¼ 4.91 (SD ¼ .37)
with signiﬁcant values of (p < .01) and (p < .0001), respectively
(see Table 3).
Correlational analysis was performed for patient reported NRS
pain scores, as well as morphine sulfate equivalency scores in the
PACU, POD#0, POD#1, and POD#2. All correlations were signiﬁcant
at the p < .0001 level, thus demonstrating a strong relationship
between patient reported pain and the pain narcotics administered
to the patient (see Table 4).
Discussion
We suspected that hospitalized TKA patients without a pre-
operative femoral nerve block will experience a non-inferior
postoperative pain control and MSO4 (morphine sulfate)rug cocktail Bupivacaine liposomal suspension
n (%)
N ¼ 35
p-value
67.31 (10.27) .429
30.68 (4.23) .575
22 (62.9) .094
13 (37.1) .094
35 (100.00) 1.000
0 (.00) 1.000
.969
2 (5.71)
19 (54.29)
14 (40.00)
.101
6 (17.14)
29 (82.86)
4 (11.43) .673
3 (8.57) .690
22 (62.86) .334
1 (2.86) 1.000
9 (25.71) .011a
Table 3
Reported pain scores and morphine sulfate equivalency between groups.
Total sample
n (%)
N ¼ 70
Concentrated multi-drug cocktail
n (%)
N ¼ 35
Bupivacaine liposomal suspension
n (%)
N ¼ 35
p-value
NRS scores
PACU, Mean (SD)d 2.80 (2.84) 3.49 (2.87) 2.11 (2.68) .033a
POD#0d 3.24 (1.81) 3.60 (1.77) 2.89 (1.81) .114
POD#1d 2.94 (1.45) 3.31 (1.55) 2.57 (1.27) .023a
POD#2d 2.96 (1.60) 3.51 (1.54) 2.40 (1.48) .002
POD#3 4.00 (1.31) 4.00 (1.83) 4.00 (.82) e
MS04 equivalency scores (mg)
PACUd 4.92 (6.51) 6.85 (6.57) 2.99 (5.93) .002a
POD#0d 7.81 (7.04) 8.73 (7.48) 6.89 (6.56) .267
POD#1d 13.24 (9.65) 15.57 (10.91) 10.91 (7.67) .079
POD#2d 10.00 (10.66) 13.11 (13.30) 6.89 (5.79) .005b
POD#3 13.75 (10.94) 16.25 (16.01) 11.25 (2.50) e
Post op 10 day Likert score
Hospital Pain control Satisfactiond 4.51 (.78) 4.11 (.87) 4.91 (.37) .0001c
Overall Pain control Satisfactiond 4.27 (.83) 3.97 (.86) 4.57 (.70) .001b
POD ¼ Postoperative day.
a Statistically signiﬁcant at the p < .05 level.
b Statistically signiﬁcant at the p < .01 level.
c Statistically signiﬁcant at the p < .001 level.
d ManneWhitney U Test.
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caine liposome. Bupivacaine liposome pericapsular injection, as
part of a pain management approach, was shown to be non-
inferior.
This study demonstrated a difference in patient-reported pain
scores, morphine sulfate equivalency consumption, adverse events,
and overall satisfaction for patients receiving a pericapsular injec-
tion of bupivacaine liposome versus a multi-drug cocktail. Indi-
vidual differences between study groups were accounted for by
showing no statistically signiﬁcant differences, thus making our
ﬁndings valid.
Nausea and vomiting were signiﬁcantly less prominent in the
bupivacaine liposome group versus the concentrated multi-drug
cocktail group, which has the potential to help improve overall
patient satisfaction with the operative and recovery experience.
Pain control has a direct bearing on patient satisfaction by limiting
opioid consumption which can reduce the potential for adverse
drug reactions and a prolonged recovery [19]. In addition; less
reliance on nerve blocks could reduce the amount of postoperative
falls and allow for accelerated ambulation [20]. Early mobilization
and positive patient outlook are arguably some of the more inﬂu-
ential factors contributing to good postoperative TKA rehabilita-
tion. In preparation for shorter hospital stays for total joint
arthroplasty programs, prevention and effective relief of post-
operative pain is needed and could subsequently contribute to
advanced healing, rapid mobilization, and reduced health care
costs [21].
Limitations are recognized within this study. The results can
only be applied to the study population using the methods andTable 4
Correlations between patient reported NRS scores and MSO4 equivalency scores.
MS04 equivalency scores
MS04 total score PACU MS04 total
NRS pain scores
Post-op pain score PACUa r ¼ .785 (.0001)
POD#0 Pain scorea r ¼ .511 (.0
POD#1 Pain scorea
POD#2 Pain scorea
a Statistically signiﬁcant at the p < .0001 level.procedures described for this study. Postoperative pain control
cannot be generalized to every type of surgical procedure; though
possibly all extremity surgery patients might beneﬁt. Other
methods must be in place in order to help with those patients
whose pain might not be controlled with the pericapsular injection
alone, such as the option to use rescue opioid pain medications.
Also, different anesthesia techniques are used on patients based on
past medical history and anatomy. Some patients receive neuraxial
anesthesia while others undergo general anesthesia, thus missing
the pre-emptive pain remitting beneﬁt of neuraxial anesthesia. In
these patients, bridging soft tissue Marcaine HCL injections might
be beneﬁcial.
This study demonstrated a novel approach for examining the
differences between bupivacaine liposomal injection versus a
multi-drug cocktail suspension standard of care approach on pa-
tient perceived pain narcotic consumption and overall patient
satisfaction around a TKA. Due to the study limitations andminimal
clinical signiﬁcance, more research is needed to clarify the differ-
ences in pain scores and patient satisfaction with overall pain
control in various combinations of anesthesia and pericapsular
injections. Also, bupivacaine liposome injection techniquesmust be
scrutinized to determine if injection methods vary and if variances
could adversely affect pericapsular injection pain control. This
study was one of the ﬁrst of its kind to examine the Bupivacaine
liposomal suspension for patients receiving a TKA without a
femoral nerve block. It is the ﬁrst known study that used a level 1
double-blinded randomized control research method to investi-
gate, in total knee patients, and to prove the beneﬁt of bupivacaine
liposome over a commonly utilized multi-drug injection method.score POD#0 MS04 total score POD#1 MS04 total score#2
001)
r ¼ .687 (.0001)
r ¼ .577 (.0001)
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In light of patient dissatisfaction with postoperative pain man-
agement and the enlarging national narcotic abuse crisis, it is
arguably the primary burden for innovative surgeons to further
enhance multimodal pain management strategies. Pre-emption of
surgical pain, non-narcotic analgesic and neuroleptic medications,
accelerated physical therapy, optimized patient expectations, and
avoidance of excessive pain and almost all complications will
remain the targets for evidence-based research discoveries and
translations into clinical practice. Surgeons' sole reliance on
narcotic control of postoperative pain was never the best way to
ensure patient satisfaction and safety, particularly since narcotics
are among the medications most likely to contribute to short- and
long-term adverse events.
Pericapsular injections with prolonged acting agents, coupled
with tourniquet-less and tissue-sparing surgical techniques might
well emerge as some of the brightest stars on our joint recon-
structive horizon. We must lead with evidence-based research
designs and publications so that broader adoption can beneﬁt most
joint arthroplasty patients. Value-based health care improvements
will always beneﬁt from safer and more effective postoperative
pain control strategies that avoid prolonged patient recoveries and
narcotic addictions.References
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